Literature DB >> 10047584

Structural insights into the function of type IB topoisomerases.

M R Redinbo1, J J Champoux, W G Hol.   

Abstract

Topoisomerases relax the DNA superhelical tension that arises in cells as a result of several nuclear processes, including transcription, replication and recombination. Recently determined crystal structures of human topoisomerase I in complex with DNA and of the 27 kDa catalytic domain of the vaccinia virus topoisomerase have advanced our understanding of the eukaryotic type IB topoisomerases. These recent structural results provide insights into functional aspects of these topoisomerases, including their DNA binding, strand cleavage and religation activities, as well as the mechanism that these enzymes use to relax DNA superhelical tension. In addition, two proposed models of the anticancer drug camptothecin bound to a covalent complex of human topoisomerase I and DNA suggest a structural basis for the mode of action of the drug.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10047584     DOI: 10.1016/s0959-440x(99)80005-0

Source DB:  PubMed          Journal:  Curr Opin Struct Biol        ISSN: 0959-440X            Impact factor:   6.809


  17 in total

1.  Two tricks in one bundle: helix-turn-helix gains enzymatic activity.

Authors:  N V Grishin
Journal:  Nucleic Acids Res       Date:  2000-06-01       Impact factor: 16.971

2.  Self-generated DNA termini relax the specificity of SgrAI restriction endonuclease.

Authors:  Jurate Bitinaite; Ira Schildkraut
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-29       Impact factor: 11.205

3.  DNA relaxation by human topoisomerase I occurs in the closed clamp conformation of the protein.

Authors:  James F Carey; Sharon J Schultz; Lisa Sisson; Thomas G Fazzio; James J Champoux
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-23       Impact factor: 11.205

4.  Protein concerted motions in the DNA-human topoisomerase I complex.

Authors:  Giovanni Chillemi; Paola Fiorani; Piero Benedetti; Alessandro Desideri
Journal:  Nucleic Acids Res       Date:  2003-03-01       Impact factor: 16.971

5.  Residues 190-210 of human topoisomerase I are required for enzyme activity in vivo but not in vitro.

Authors:  Morten O Christensen; Hans U Barthelmes; Fritz Boege; Christian Mielke
Journal:  Nucleic Acids Res       Date:  2003-12-15       Impact factor: 16.971

Review 6.  Probing enzyme phosphoester interactions by combining mutagenesis and chemical modification of phosphate ester oxygens.

Authors:  James T Stivers; Rajesh Nagarajan
Journal:  Chem Rev       Date:  2006-08       Impact factor: 60.622

7.  New peptide inhibitors of type IB topoisomerases: similarities and differences vis-a-vis inhibitors of tyrosine recombinases.

Authors:  David F Fujimoto; Clemencia Pinilla; Anca M Segall
Journal:  J Mol Biol       Date:  2006-08-24       Impact factor: 5.469

8.  An insight into the active site of a type I DNA topoisomerase from the kinetoplastid protozoan Leishmania donovani.

Authors:  Aditi Das; Chhabinath Mandal; Arindam Dasgupta; Tanushri Sengupta; Hemanta K Majumder
Journal:  Nucleic Acids Res       Date:  2002-02-01       Impact factor: 16.971

9.  Alleviating cancer drug toxicity by inhibiting a bacterial enzyme.

Authors:  Bret D Wallace; Hongwei Wang; Kimberly T Lane; John E Scott; Jillian Orans; Ja Seol Koo; Madhukumar Venkatesh; Christian Jobin; Li-An Yeh; Sridhar Mani; Matthew R Redinbo
Journal:  Science       Date:  2010-11-05       Impact factor: 47.728

10.  Resolution of a Holliday junction by vaccinia topoisomerase requires a spacer DNA segment 3' of the CCCTT/ cleavage sites.

Authors:  J Sekiguchi; C Cheng; S Shuman
Journal:  Nucleic Acids Res       Date:  2000-07-15       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.